Seventeen patients with Huntington's disease were randomly assigned to receive, in double-blind fashion, a supplement containing unsaturated fatty acids or a placebo. The dosage of unsaturated fatty acids was eight 1-g capsules per day; each capsule contained 70 mg of gamma-linolenic acid (GLA), 35 mg of eicosapentaenoic acid (EPA), 20 mg of docosahexaenoic acid (DHA), 50 mg of alpha-lipoic acid, and 30mg of vitamin E, with linoleic acid as a carrier. The placebo contained hydrogenated coconut oil, alpha-lipoic acid, and vitamin E. The mean duration of treatment was 19 months for active treatment and 20 months for placebo. On the Rockland-Simpson Dyskinesia Rating Scale, 7 patients receiving active treatment improved and 2 became worse, whereas 1 patient receiving placebo improved, 1 was unchanged, and 6 became worse (p = 0.01 for the difference in the response between groups). A similar trend (p = 0.08) was seen using the Unified Huntington's Disease Rating Scale. No significant side effects were seen.
Comment: Huntington's disease is a hereditary, progressive degenerative brain disorder that eventually results in death. Because no effective conventional treatment is available, the results of this new study are encouraging. In another recent double-blind study (Neuroreport 2002;13:123-6), supplementation with the ethyl-ester of EPA (1 g twice a day for 6 months) resulted in significant improvement in motor function in patients with Huntington's disease. In addition, each of two patients in the active-treatment group who underwent MRI brain scans before and after treatment showed a reversal of cerebral atrophy. These two studies of unsaturated fatty acids offer new hope in the treatment of this devastating disease.
Vaddadi KS, et al. A randomised, placebo-controlled, double blind study of treatment of Huntington's disease with unsaturated fatty acids. Clin Neurosci Neuropathol 2002;13:29-33.
COPYRIGHT 2003 The Townsend Letter Group
COPYRIGHT 2003 Gale Group